Kulkarni Reshma, Sapkal Gajanan N, Kaushal Himanshu, Mourya Devendra T
ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune-411001, India.
Open Virol J. 2018 Aug 31;12:121-130. doi: 10.2174/1874357901812010121. eCollection 2018.
Japanese encephalitis (JE) is recently declared as a notifiable disease in India due to its expanding geographical distribution. The disease notification facilitates effective implementation of preventive measures and case management.
JE is a vector-borne disease that can be prevented by vaccine administration. It is caused by Japanese encephalitis virus (JEV), belonging to family . Amongst the known etiological viral encephalitis agents, it is one of the leading viral agents of acute encephalitis syndrome in many Asian countries where it is identified to cause substantial morbidity and mortality as well as disability. Globally, it is responsible for approximately 68,000 clinical cases every year.
In the absence of antivirals, patients are given supportive treatment to relieve and stabilize. Amongst available control strategies; vector control is resource intensive while animal and human vaccination are the most effective tool against the disease. This review highlights recent progress focusing challenges with diagnosis and prophylactic interventions.
由于日本脑炎(JE)的地理分布不断扩大,印度最近宣布将其列为须上报疾病。疾病通报有助于有效实施预防措施和病例管理。
日本脑炎是一种可通过接种疫苗预防的媒介传播疾病。它由日本脑炎病毒(JEV)引起,属于 科。在已知的病毒性脑炎病原体中,它是许多亚洲国家急性脑炎综合征的主要病毒病原体之一,在这些国家,它被认定会导致大量发病、死亡以及残疾。在全球范围内,它每年导致约68000例临床病例。
在没有抗病毒药物的情况下,给予患者支持性治疗以缓解症状并使其稳定。在现有的控制策略中,病媒控制资源密集,而动物和人类疫苗接种是对抗该疾病最有效的工具。本综述重点介绍了近期在诊断和预防性干预方面面临挑战的进展。